Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Abstract: COPD is a complex, heterogeneous disease. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.

Keywords: dual bronchodilation, inhaled corticosteroid, LAMA, LABA, tiotropium, anticholinergic

Introduction
COPD is a progressive lung disease characterized by airflow obstruction that results in breathlessness and disability. COPD carries a significant burden for patients and health-care systems alike, and rates are reported to be increasing. In fact, COPD is now the third-leading cause of death worldwide. In a population-based worldwide study (BOLD initiative), the prevalence of COPD (GOLD stage 2 or higher) identified by postbronchodilator spirometry and questionnaires among individuals of age ≥40 years was 10.1%. Although a certain proportion of COPD cases remain undiagnosed and the recorded prevalence rates vary among countries, approximately 15%–17% of current smokers and as many as 4%–12% of non- or ex-smokers develop COPD. COPD limits daily activities, affecting work and family life. A substantial proportion of patients with mild–moderate COPD (GOLD stage 1 and 2) report poor health, impaired health-related quality of life (HRQoL), and exercise limitation, often associated with dynamic hyperinflation during daily activities. Indeed, according to a recent report by O’Donnell et al, patients with COPD stage 1 and 2 have both impaired exercise capacity and increased breathlessness at isotonic exercise when compared with age- and sex-matched controls. Impairment in exercise tolerance may in turn promote a sedentary lifestyle in patients with COPD, with inactivity levels rising dramatically over the course of the disease. Furthermore, more than a third of patients with mild airflow limitation develop COPD exacerbations, with...
a subsequently heightened risk of future exacerbations.\textsuperscript{18} Importantly, half of the patients with mild exacerbations of COPD do not report them as such at clinical visits, although exacerbations have been demonstrated to influence QoL and daily activities.\textsuperscript{19} Importantly, even mild–moderate COPD, especially when presenting with symptoms of chronic bronchitis, has been associated with increased mortality.\textsuperscript{20,21}

This article summarizes the current scientific evidence and expert opinion on key topics related to the pharmacological treatment of moderate COPD. These include the symptom burden associated with moderate airflow obstruction, the relevance of physical activity on disease outcomes, the value of long-acting dual bronchodilation, and the role of inhaled corticosteroids (ICSs) in COPD. For this purpose, experts from the COPD Platform, a collaboration among physicians from eleven Central and Eastern European countries, aimed at further understanding COPD and conducting clinical research in the region,\textsuperscript{22} discussed the mentioned topics during a roundtable discussion in April 2016, and together with invited experts subsequently analyzed the scientific evidence via multiple exchanges over email.

**Risk factors and lung-function decline in COPD**

Smoking is a widely acknowledged risk factor for COPD. According to a recent Finnish study, 11.4\% and 22.8\% of a cohort of heavy smokers had developed COPD by 3 and 6 years of follow-up, respectively.\textsuperscript{23} Developing COPD, however, does not solely depend on smoking exposure. Lange et al showed that 26\% of people under the age of 40 years who had low baseline forced expiratory volume in 1 second (FEV\textsubscript{1}; <80\% predicted) had developed COPD within 22 years of observation compared with 7\% of those with baseline FEV\textsubscript{1} >80\%.\textsuperscript{24} These findings suggest that early-life risk factors may contribute to COPD beyond the effects of smoking. In fact, in a European study conducted over 9 years, patients aged 20–45 years with one or more childhood disadvantage factors (maternal asthma, paternal asthma, childhood asthma, maternal smoking, or childhood respiratory infections) showed significantly lower FEV\textsubscript{1} levels than other patients of the same age. The degree of FEV\textsubscript{1} decrease correlated with the number of risk factors present, as did the presence of COPD at study close.\textsuperscript{25}

Awareness of such risk factors may lead to earlier interventions and potentially to a reduction in the delays seen in achieving a diagnosis of COPD. The absence of spirometry data in clinical practice is a major contributor to delays in patient diagnosis.\textsuperscript{26,27} This may result in unobserved disease progression and subsequent clinical presentation of more advanced disease.\textsuperscript{28–30} Indeed, in a subset of 366 patients with COPD identified from a US patient database, 50\% suffered from moderate disease (GOLD 2) at the time of diagnosis, while 31\% already had GOLD 3 (severe) or GOLD 4 (very severe) COPD.\textsuperscript{31}

Such delays in diagnosing COPD may have several implications. In a large multicenter study, Dransfield et al observed lung-function decline over 5 years at a greater rate in patients with mild–moderate (GOLD 2) COPD than in those with more severe disease.\textsuperscript{32} According to another study, the fastest decline in FEV\textsubscript{1} occurs during even mild (GOLD 1) COPD.\textsuperscript{33} The decline in lung function was increased further in patients who had already suffered a severe exacerbation at the time of the first visit (Figure 1).\textsuperscript{34} Therefore, preserving lung function early in the course of the disease may be considered an important goal of therapy to reduce morbidity and mortality.\textsuperscript{34–36}

From a therapeutic point of view, it is needless to say that smoking cessation at any stage of the disease can prevent clinically significant airway obstruction and slow down the rate of decline in lung function,\textsuperscript{37} thus benefiting long-term outcomes.\textsuperscript{38} This effect is independent of sex, age, or baseline lung function, indicating that it is never too late to derive benefit from smoking cessation.

**Rationale for maximizing bronchodilation in patients with moderate COPD**

Long-acting muscarinic antagonists (LAMAs) selectively block receptor binding to reduce the bronchoconstrictive effects of acetylcholine on smooth-muscle cells in the...
lungs. Long-acting β2-adrenoceptor agonists (LABAs) further promote a bronchodilation effect through smooth-muscle relaxation via the β2-adrenergic receptors and through inhibition of acetylcholine release. On the other hand, anticholinergics interfere with PKC inhibition of the downstream signaling of the β2-adrenergic receptor. It is worth noting that with LAMAs acting predominantly within the proximal sections of the lung and LABAs typically within the distal sections, they provide a complementary effect on lung function. Treating patients with moderate COPD using bronchodilators may help to preserve and protect lung function, increase exercise capacity, reduce exacerbation rates, and reduce symptoms, resulting in better health status, lower disease burden, and improvements in overall QoL. In fact, a recent study of inhaled tiotropium in patients with early-stage chronic COPD (GOLD stage 1 or 2) indicated that the annual decline in FEV1 measured after bronchodilator use was significantly less in the tiotropium group than the placebo group (29±5 mL per year vs 51±6 mL per year, P=0.006), indicating a potentially disease-modifying effect of long-acting anticholinergic therapy when established early in the disease course. Whether these benefits extend to the level of a survival benefit remains to be established. Post hoc analyses of both the TORCH and UPLIFT studies suggested a survival benefit of sustained bronchodilation in moderate-severe COPD; however, these findings have not been formally proven in prospective studies.

There is emerging scientific evidence for the use of fixed-dose combinations of LAMAs and LABAs with the intention of achieving maximal and sustained bronchodilation with subsequent clinical benefits. In this context, we discuss results from recent randomized controlled trials (RCTs) investigating the effects of dual bronchodilation on various clinical outcome measures in patients with COPD. Clinically meaningful improvements in HRQoL have been recorded with the fixed-dose combination of tiotropium and olodaterol, showing improvements in St George’s Respiratory Questionnaire (SGRQ) total score after 12 weeks by 4.89 versus placebo and 2.49 versus tiotropium alone. Importantly, the incidence of adverse events is comparable between the fixed-dose combination and tiotropium or olodaterol monotherapy. When considering these results, it should be noted that the patient populations in these studies varied, with the inclusion of high proportions of patients with moderate COPD (GOLD stage 2) or comorbidities, as well as pretreated and treatment-naïve patients.

Other dual-action bronchodilator combinations have shown similar benefits. Donohue et al conducted a 24-week study of umecclidinium (UMEC)–vilanterol (VI) against the individual components or placebo, finding that all active treatments produced statistically significant improvements in trough FEV1 compared with placebo on day 169 (0.072–0.167 L, all P<0.001), that the increase in trough FEV1 with UMEC (62.5–VI (25 µg) was significantly greater than with mono-therapies (0.052–0.095 L, P=0.004), and that statistically significant HRQoL improvements were seen in SGRQ scores compared with placebo. In the SHINE study, an indacaterol and glycopyrronium combination was assessed against the individual components in patients with moderate–severe COPD. Trough FEV1 was statistically higher in the combination arm than the single agents (P<0.001). SGRQ scores in
this study at week 12 were statistically higher for the combination than placebo ($P<0.001$) and glycopyrronium ($P=0.02$), but this finding was not seen against indacaterol or with any single agent vs placebo. Overall, there is increasing evidence for a beneficial effect of dual bronchodilation in patients with COPD compared with single agents.

**Bronchodilators and exercise limitation**

Patients in the early stages of COPD suffer from noticeable breathlessness on exertion, predominantly owing to dynamic hyperinflation,$^{13,64}$ and this phenomenon is present even during daily activities.$^{14}$ In turn, dyspnea during exercise is likely to contribute to the significant drop in activity levels seen in patients with mild–moderate COPD.$^{15}$ A controlled multicenter study by Troosters et al involving 70 patients with COPD and 30 healthy controls demonstrated a 29% reduction in the number of steps per day and a 59% reduction in the time spent on activities at moderate intensity in patients with GOLD stage 2 COPD compared with control individuals.$^{65}$ Sedentary behavior and lack of physical activity are strong and independent predictors of all-cause mortality in COPD.$^{66–69}$ Taking steps to maintain regular exercise thus has a positive impact on QoL and COPD progression,$^{67}$ preventing a downward spiral in physical function and conditioning.$^{70}$ Indeed, pulmonary rehabilitation (PR) is regarded as being one of the most effective nonpharmacological treatments for people with COPD, leading to improvements in exercise tolerance, dyspnea, and HRQoL.$^{71,72}$ Importantly, some of these benefits may be achieved by improvements in accessible alveolar lung volume, whereas patients with severe diffusion-capacity impairment and presence of ventilation inhomogeneity appear to experience smaller improvements in exercise tolerance.$^{73}$ By the addition of a long-acting anticholinergic bronchodilator to PR, clinically meaningful improvements in dyspnea and health status have been seen over PR alone.$^{74}$ Studies on the effect of dual bronchodilation in association with PR in patients with COPD are still lacking.

It may be suggested that improving lung function and reducing elevated lung volume by sustained bronchodilation can reduce dynamic hyperinflation in COPD and thus contribute to patients’ improved exercise tolerance. The introduction of dual-bronchodilator treatments into real-life clinical practice may further facilitate increased exercise capacity.$^{75,76}$ In a 12-week, double-blind, placebo-controlled study involving 404 patients, combined tiotropium and olodaterol provided a 21% improvement in endurance shuttle walking versus placebo.$^{77}$ Similarly, a double-blind, double-dummy, three-period crossover study of 85 patients revealed that combined glycopyrronium and indacaterol significantly improved patients’ exercise endurance time compared with placebo.$^{76}$ Once published, the recently completed PHYSACTO$^{77}$ study should provide additional clarity on the physical activity benefits of dual bronchodilation. This randomized, partially double-blinded, placebo-controlled, parallel-group trial involving patients from 34 multinational sites looks at multicomponent interventions (tiotropium, tiotropium + olodaterol, or tiotropium + olodaterol + exercise training) that are designed to support behavior change related to physical activity.$^{77}$ Recently, the MORACTO 1 and 2 studies assessed the effects of tiotropium–olodaterol on inspiratory capacity and exercise-endurance time in patients with moderate–severe COPD. Tiotropium (2.5/5 µg)–olodaterol (5/5 µg) provided significant improvements in inspiratory capacity versus placebo and monotherapies ($P<0.0001$) and significant improvements in exercise-endurance time versus placebo ($P<0.0001$).$^{78}$ It would be of interest to perform a prospective study to assess PR by directly comparing a LAMA-LABA combination plus PR to the LAMA-LABA combination alone.

However, a number of questions remain unanswered in this context. Will the patients with COPD actually improve their activity levels in a real-life setting after the initiation of optimal bronchodilator treatment? Is there a threshold of irreversibility with regard to physical deconditioning based on biological grounds, such as systemic inflammation? And what is the role of such comorbidities as heart failure in exercise-capacity limitations?

**The effect of bronchodilators on exacerbation rates in COPD**

An important consideration in the treatment of COPD is the prevention of exacerbations. Although ICSs have been traditionally viewed as the main treatment for patients at risk of exacerbations (especially for postbronchodilator FEV$_1 \leq$50% predicted value), there is accumulating evidence to suggest an important role for bronchodilators in the prevention of exacerbations.$^{79–82}$ In a previous clinical trial conducted in 37 countries, 5,993 patients were randomized to receive 4 years of treatment with either 18 µg once-daily tiotropium or placebo delivered by matching inhalation devices. The results showed that tiotropium significantly reduced exacerbation rates versus placebo in largely pretreated (with medicines other than LAMAs) patients with GOLD stage 2 COPD.$^{46}$
Vogelmeier et al subsequently demonstrated superiority of LAMAs over LABAs in reducing exacerbation rates in COPD, suggesting the presence of various mechanisms and pathways that anticholinergic and \( \beta_2 \)-sympathomimetic agents affect, leading to fewer exacerbations.\(^8\) A similar signal was observed in patients with severe COPD when using a LABA with 24-hour efficacy.\(^8\) Combining LAMA and LABA agents, however, may exert additive effects that could further reduce the number of exacerbations in COPD. Indeed, combination of sustained bronchodilation with subsequent lung-volume reduction might contribute to patent airways, thus protecting patients from fluctuations in the severity of airflow obstruction that potentially lead to an exacerbation.\(^50,85\) A recent study investigating the effects of tiotropium and indacaterol on stable patients with moderate–severe COPD showed that the vital capacity in these patients had increased at 1 hour postadministration, but not the transpulmonary pressure curve, indicating that it is possible to achieve a positive effect on gas exchange without risking small-airway damage.\(^86\)

Furthermore, in addition to having low-level anti-inflammatory effects, both LAMAs and LABAs have demonstrated reductions in mucus production and improvements in mucus clearance, which in turn may reduce exacerbation risk by a robust increase in the threshold of sensitivity to exacerbation-precipitating triggers.\(^87–89\) Finally, bronchodilators have been demonstrated to reduce both cardiac preload and afterload, thus improving cardiac function.\(^90\) Given that left heart failure is considered an important trigger of COPD exacerbations,\(^94\) improvements in cardiovascular morbidity associated with long-term maintenance-bronchodilator treatment may contribute to the stability of COPD.\(^92,93\)

As expected, a combination of two bronchodilators may significantly improve lung function compared with the combination of a single bronchodilator (usually a LABA) with an ICS. Indeed, Rabe et al demonstrated superiority of a free combination of tiotropium and formoterol over a fixed-dose combination of salmeterol and fluticasone for FEV\(_1\), AUC.\(^94\) These findings were further strengthened by the introduction of fixed-dose combination dual-bronchodilator therapy. After 6 weeks of once-daily dual bronchodilation with tiotropium (5/5 μg) and olodaterol (2.5/5 μg) compared with twice-daily salmeterol (50/500 μg) and fluticasone propionate (50/250 μg), statistically significant improvements were seen in FEV\(_1\), AUC\(_{0–12}\) (\(P<0.0001\) for all comparisons).\(^50\) The combination of tiotropium and olodaterol was also superior to the combination of salmeterol and fluticasone propionate for improving secondary lung-function end points, including FEV\(_1\), AUC\(_{0–24}\) (\(P<0.0001\) for all comparisons). A fixed-dose combination of indacaterol and glycopyrronium similarly offered a significant and clinically meaningful improvement in FEV\(_1\), AUC\(_{0–12}\) at week 26 compared with that achieved with a combination of salmeterol and fluticasone.\(^95\) Similar findings with respect to lung-function improvements over LABA-ICS combinations have been observed with other dual-bronchodilator combinations, such as umeclidinium–vilanterol\(^96\) and aclidinium–formoterol.\(^93,97\)

A previous post hoc analysis from a clinical trial of LAMA-LABA versus LABA-ICS combinations demonstrated lower exacerbation rates with the dual-bronchodilator combination, indicating that the aforementioned pleiotropic effects of dual bronchodilation may be more potent than the anti-inflammatory effects of ICSs on the course of COPD. More recently, results from a prospective RCT (FLAME) confirmed superiority of LAMA-LABA over LABA-ICS combinations in reducing exacerbation rates in patients with COPD at risk of exacerbations.\(^52\) This study was a year-long RCT designed to compare the annual number of COPD exacerbations as the primary end point between LAMA-LABA (indacaterol–glycopyrronium once daily) and LABA-ICS (salmeterol–fluticasone twice daily) study groups. The LAMA-LABA combination not only showed noninferiority but also superiority over the LABA-ICS combination with an 11% lower annual rate of COPD exacerbations plus a 16% lower risk of exacerbation reflected in a longer time to first exacerbation in the LAMA-LABA group versus the LABA-ICS group.\(^52\) However, it should be noted that “noninferiority only” was demonstrated for the 20% of patients with COPD in the study who had a history of two or more exacerbations. This is of specific importance, as in the recent GOLD guidelines,\(^99\) patients are stratified into different risk groups with respective treatment recommendations based on symptom load and exacerbation history, but not on FEV\(_1\). Indeed, a recent analysis from a cohort of 3,500 patients with stable COPD in Central and Eastern Europe\(^98\) showed that 35% of patients in group D according to the previous version of the GOLD guidelines\(^100\) would move to group B according to the GOLD 2017 revision, because of a lack of real exacerbations.\(^101\) Of note, the majority of these patients (71%) were on ICS treatment, and according to GOLD 2017 should not receive ICSs any longer. It remains to be determined whether and to what extent the guideline recommendations on the use of ICS-containing regimens will be translated into real-life prescription behavior.\(^99\) Furthermore, these studies were undertaken using LABA-ICS combinations, so until the results of ongoing research to address the effect and role of
Several factors contribute to the powered by TCPDF (www.tcpdf.org) for personal use only.

found a statistically significant 19% survival advantage to the cant survival benefit. However, post hoc factorial analysis often perceived as “almost achieving” a statistically signifi

demonstrate superiority over treatment with single bronchodila

tors for moderate–severe exacerbation rates will be assessed in the Phase III DYNAGITO trial, which is a prospective RCT investigating a tiotropium-containing LAMA-LABA combination versus bronchodilator monotherapy.

On the basis of the accumulating evidence for dual bronchodilators with respect to lung function, symptoms, HRQoL, and exacerbation rates, first-line treatment with LAMA-LABA fixed-dose combinations may be considered in the majority of treatment-naïve patients with symptomatic COPD. In contrast, the role of ICS-containing drug regimens in COPD needs further personalized evaluation.

The role of ICSs in COPD
ICS monotherapy in COPD

The paradigm of beneficial effect of ICSs in asthma and the similarity of airway symptoms in the two diseases have led to the use of ICSs being extended to COPD. However, unlike asthma, steroid resistant inflammation occurs in most patients with COPD, explaining the ineffectiveness of ICSs in this disease. Early trials of ICSs in COPD conducted prior to the availability of long-acting bronchodilators showed symptomatic benefit without affecting FEV₁ decline or mortality. The main beneficial effect of ICSs in COPD, a modest decrease in moderate–severe exacerbations was largely limited to patients with severe airflow limitation. Critical appraisal revealed important methodological issues that underlay a significant overestimate of this salutary effect.

ICS-LABA in COPD

When ICS-LABA combination inhalers became available, the problem of “copy-pasting” ICS-based asthma therapies onto COPD recurred. The TORCH RCT investigated the effects of an ICS-LABA combination on mortality and key secondary outcomes in severe COPD. This trial, notable for complete follow-up (intention-to-treat) for survival, is often perceived as “almost achieving” a statistically significant survival benefit. However, post hoc factorial analysis found a statistically significant 19% survival advantage to the LABA component (salmeterol), but not to the ICS component (fluticasone). Interpretation of the TORCH results pertaining to benefits in exacerbations and decline in FEV₁ and QoL is prone to bias of differential dropout, owing to incomplete follow-up for these secondary end points.

ICS use as per GOLD reports

Since 2011, in acknowledgment of the aforementioned observations and the demonstrated superiority of long-acting bronchodilators over ICSs in improving lung function and exercise capacity, GOLD COPD recommendations against ICS monotherapy limited ICS use in COPD to ICS-LABA combinations only. This further emphasizes the dominant contribution of the long-acting bronchodilator (in this case, LABA) component of ICS-LABA combinations in COPD and in contrast to the dominant role of ICSs versus bronchodilators in asthma. Given the increasing evidence for the effectiveness of dual long-acting bronchodilation in improving key COPD-outcome measures, the updated GOLD 2017 report recommends that ICS-containing drug regimens be restricted to patients with severe airflow limitation and frequent exacerbations despite maximized bronchodilator treatment.

The challenge of implementing guidelines

As many as two-thirds or more of primary care physicians and a third of respiratory specialists do not follow the GOLD recommendations in clinical practice. Using a large primary-care database from the UK, Brusselle et al recently demonstrated that 25% of patients receive ICS-containing treatment within the first year of treatment initiation, with almost 100% receiving triple-inhaler therapy within 8 years of diagnosis. Similarly, both Price et al and Barrecheguren et al reported that a high proportion of patients with mild–moderate COPD were receiving ICS-based treatment in clinical practice. Several factors contribute to the discrepancy between guidelines and real-life practice. The long-standing underutilization of spirometry and unfamiliarity with its use in primary care, together with erroneous beliefs regarding the benefits of ICSs in COPD and overused asthma–COPD overlap in diagnostic labeling, all contribute to difficulties in differentiating COPD from asthma. The complexity of the GOLD classification of COPD and the ever-increasing multiplicity of inhaler options may add difficulties in proper implementation of the guidelines. Habitual prescribing patterns and existing prescriptions from a prior health-care professional may contribute to delays in the clinical implementation of recommendations from.
ICSs and pneumonia in COPD

In patients not fulfilling the aforementioned criteria, ICS use may have an unfavorable risk:benefit ratio. Prolonged ICS use in these patients has been associated with increased rates of pneumonia, tuberculosis, osteoporosis, cataracts, diabetes, and oropharyngeal candidiasis. Whether this increase is class-related or brand-related remains to be decided. Again, the TORCH trial drew attention to the adverse associations linking ICS use in COPD to the events of pneumonia. According to a recent meta-analysis, the estimated unadjusted risk of pneumonia associated with ICSs was increased in both randomized trials (RR 1.61) and in observational studies (OR 1.89), without evidence of an increase in case fatality. However, a greater number of patients with COPD receiving ICSs are hospitalized due to severe pneumonia than those not receiving ICSs; therefore, a possibility exists that more patients with COPD will die from pneumonia, even if the case-fatality rate is the same once hospitalized. The risk of pneumonia decreases, however, by 50% within 4 months of ICS discontinuation. It should be emphasized, however, that for patients in whom ICSs are correctly indicated (as detailed herein), their benefits could outweigh the increased risk of pneumonia.

Asthma and COPD overlap

In recognition of patients presenting with clinical features of both asthma and COPD, associated with an increased burden of symptoms and exacerbations, both GOLD and GINA jointly formulated a 2015 document recommending that these patients with asthma–COPD overlap should be treated with ICSs, irrespective of their lung-function impairment, to prevent asthma-related morbidity and mortality. The stated prevalence of this group of patients is 5%–45% of those with COPD, and accounted for 7% of patients with COPD in the Central and Eastern Europe POPE study. The 2017 version of the GOLD report treats asthma–COPD overlap as an overlap phenomenon, rather than a distinct syndrome, and the 2015 appendix developed by the GINA and GOLD committees addressed the difficulty of this clinical definition, suggesting several characteristic clinical features. These include a history of asthma and other respiratory symptoms before the age of 40 years, airflow limitation not being fully reversible, a history of allergies, and the presence of eosinophils and/or neutrophils in the sputum. These patients have been largely excluded from both asthma and COPD trials, meaning that there is no documented evidence on the effective management of this group. Therefore, the presumed effectiveness of ICSs in patients with asthma–COPD overlap remains to be established, especially as the underlying inflammatory endotype is often noneosinophilic and thus unresponsive to treatment with ICSs and probably also with anti-IL5.

Peripheral blood eosinophil count in COPD

Evidence of eosinophilic inflammation using blood eosinophilia as a surrogate marker may be a useful predictor of a beneficial response to ICS treatment in COPD, as higher effectiveness of ICS-containing regimens on lung function and exacerbations has been reported in patients with COPD who have higher peripheral blood eosinophil counts. A reanalysis of the former ISOLDE study suggests that a baseline blood eosinophil count ≥2% identifies those patients with COPD who may benefit from ICS-containing regimens, leading to a reduction in the rate of decline in FEV1. Some patients with COPD have predominantly eosinophilic inflammation and might respond to high doses of ICSs and newly developed antieosinophil therapies. Recent results indicated that patients with GOLD 3 or GOLD 4 COPD and eosinophil counts of more than 300 cells/µL (or 4%) were more likely to experience exacerbations following ICS withdrawal. In the GOLD 2017 revised guidelines, however, the current use of blood eosinophils to guide ICS treatment in COPD is not recommended, owing to the lack of prospective RCTs using circulating eosinophils to titrate and/or target the use of ICSs in treating the disease. Except where concomitant asthma is present, the inclusion of ICSs based on peripheral eosinophil count requires further validation before it can be generally recommended in therapeutic regimens for patients with COPD.

ICS withdrawal in COPD

Previous studies have indicated that abrupt withdrawal of ICSs increases the risk of exacerbations and results in some worsening of lung function. A recent review of RCTs involving ICS withdrawal, however, supports the withdrawal of ICSs in patients with moderate COPD at low risk of exacerbation who are receiving adequate background therapy with long-acting bronchodilators. The recent WISDOM
study demonstrated that apart from a mild 40 mL decrease in FEV$_1$, there was no increase in exacerbation risk after ICS withdrawal in patients with severe COPD on triple-inhaler therapy. Importantly, the WISDOM study assessed the possibility of stepwise withdrawal of ICSs from patients with GOLD stage 3–4 COPD and a history of at least one exacerbation during the previous 12 months. Following 6 weeks of treatment with tiotropium, salmeterol, and fluticasone, patients were randomized for ongoing treatment or stepwise reduction of ICSs. Over the 3-month withdrawal period, the HR for a first moderate or severe acute exacerbation was 1.06 (95% CI 0.94–1.19) with ICS withdrawal compared with continued treatment, thereby indicating non-inferiority. A recent meta-analysis of the benefit of ICS withdrawal showed mixed results; although there was no significant increase ($P<0.05$) in the rate of COPD exacerbation overall, there remained a clinically important increased risk of severe exacerbation (RR >1.2). Withdrawing was also significantly associated with decreased FEV$_1$ and HRQoL ($P<0.001$), although not in a clinically important manner. The GOLD 2017 recommendations suggest considering ICS withdrawal in patients with continuing exacerbations despite triple-inhaler therapy (ICS failure).

Although safe in selected patients, implementing ICS withdrawal in clinical practice requires both thoughtful patient management and comprehensive physician education to identify suitable patients and handle the withdrawal process. This sort of decision may be sensitive, especially in cases where patients have been on ICS-containing therapies for a long time. Recently, an algorithm was proposed that provides physicians with a practical guide for the withdrawal of ICSs. Building on the GOLD recommendations, the GINA–GOLD consensus statement on the asthma–COPD overlap phenotype, and the WISDOM trial, the algorithm provides a stepwise approach to identifying appropriate patients and managing ICS withdrawal.

Consistent with this stepwise recommendation and a recent proposal of phenotype-driven therapy, the following was suggested:

1. Review and optimize current COPD management, ensuring clinical stability and optimal long-acting bronchodilator background therapy
2. Evaluate the risk–benefit profile of continuing ICSs; in particular, identify whether the patient has asthma–COPD overlap and/or severe airflow limitation with evidence of eosinophilia and frequent exacerbations; if this is the case, continuation of ICSs is currently warranted
3. If the patient does not fulfill the criteria specified in point 2, first ensure optimized bronchodilation with LAMA-LABA treatment, then perform a stepwise withdrawal of ICSs, reducing the dose every 6–12 weeks
4. Follow-up every 3 months for the first year.

Although further validation is required, this proposed algorithm represents an important first step in the safe and effective management of ICS withdrawal.

**Conclusion**

There is increasing clinical evidence for the effectiveness of fixed-dose combination dual-bronchodilator treatment in achieving improved patient-related outcomes and decreasing the burden of moderate COPD. Based on clinical improvements, lung-function benefits, and reduced exacerbation rates, together with a favorable safety profile, LAMA-LABA combinations may be considered the first-line treatment for the majority of patients with moderate or severe COPD. Adding an ICS component should generally be reserved for targeted use in patients with frequent exacerbations despite dual bronchodilation with a fixed-dose combination and in patients with a history of and/or clinical signs of asthma. Stepwise ICS withdrawal should be considered in patients with COPD and low exacerbation risk and in those with repeated exacerbations despite triple-inhaler therapy.

The current availability of a plethora of inhalers for COPD management has both advantages and disadvantages. In particular, unfamiliarity with the different classes and functions of the agents, especially among general practitioners, can lead to confusion of both patients and prescribing physicians. While there is an ongoing need for new classes of therapy, comprehensive patient care must also include appropriate education regarding adherence and inhaler technique, as well as nonpharmacological therapies, mainly PR, to ameliorate the frailty of patients with COPD.

**Acknowledgments**

This manuscript was prepared with editorial assistance from Fortis Pharma Communications with financial support from Boehringer Ingelheim. All opinions are the authors’ own.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


57. Ferguson GT, Pizzichini E, Flezlar M, Grönk L, Korduski L. The fixed dose combination of tiotropium plus olodaterol has a rapid onset of action in patients with COPD. Eur Respir J. 2015;46:PA2957.


73. Ferguson GT, Pizzichini E, Flezlar M, Grönk L, Korduski L. The fixed dose combination of tiotropium plus olodaterol has a rapid onset of action in patients with COPD. Eur Respir J. 2015;46:PA2957.


